MBRX Moleculin Earnings per share growth in current year

Official company branding of moleculin.com (MBRX)

Year-over-year EPS growth rates indicate scaling potential for Moleculin Biotech, Inc. (MBRX) through the licensing of unique drug formulas. The 89.20 metric confirms the current level, which is supported by patent protection for liposomal delivery and strict FDA oversight. Price stability is ensured by the minimal impact of global conflicts and a reliable US jurisdiction that precludes trade sanctions.

moleculin.com (MBRX) Net earnings per share growth this year: for the period 07/04/2022 - 11/15/2026

Analytical breakdowns and data insights for company moleculin.com (MBRX)

- current price and projected stock value:
Quote Chart Moleculin|MBRX - Price Target Chart
- market capitalization data:
Market Value Moleculin Biotech|MBRX - Enterprise Value
- book capitalization indicators:
Book Value per Share Moleculin Biotech|MBRX - Company Net Assets|Market Cap to Book Value Multiple moleculin.com|MBRX - Company Total Assets
- debt burden and liquidity indicators:
Aggregate Debt to Equity Moleculin Biotech, Inc.|MBRX - Long-Term Debt to Equity|Current Liabilities to Capital Moleculin|MBRX - Company Debts|Debt to Net Assets Ratio Moleculin Biotech, Inc.|MBRX - Company Long-Term Debt|Company Current Liabilities Moleculin Biotech|Interim Coverage Ratio moleculin.com
- earnings and market multiples details:
MBRX - Company Net Income|Future Profit Moleculin Biotech, Inc.|MBRX - Price to Earnings Ratio|Projected Price to Earnings Ratio Moleculin|MBRX - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Moleculin Biotech|MBRX - Operating profit EBITDA|Net earnings per one share for the last twelve months Moleculin Biotech|MBRX - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months moleculin.com|MBRX - Net earnings per share growth this year|Earnings growth forecast for next year Moleculin Biotech, Inc.
- company sales and revenue statistics:
MBRX - Company Revenue|Company Projected Revenue Moleculin Biotech Inc|MBRX - P/S Multiple|Market Cap to Expected Sales Ratio Moleculin Biotech, Inc.|MBRX - Sales Growth YoY (Last Twelve Months)
Basic company analysis:moleculin.com (MBRX)
Product sample of Moleculin Biotech, Inc.

Identifying fundamentally resilient assets requires an analysis of real income dynamics. This indicator measures the relative change in earnings per share (EPS) over twelve months, reflecting the efficiency of capital generation. For Moleculin Biotech, Inc. (MBRX), this calculation demonstrates the financial return from the development of rare oncology therapies. It is critical for investors to correlate the pace of patent monetization with the annual percentage growth of net earnings per share. Analysis of this chart allows for the timely identification of the risk of overpaying for the asset.

Main competitors

Earnings per share trend in current year GERN (Geron Bio)|Earnings per share growth in current year Nanobiotix S.A.|Earnings per share growth in current year BCYC|Earnings growth in current year CTMX|Earnings growth in current year Perspective Therapeutics Inc (CATX)|Genelux - Net earnings per share growth this year|Net earnings per one share growth for the current year MOLN (Molecular Partners)|Oncolytics Biotech Inc. - Earnings growth in current year|Earnings per share trend in current year LSTA|galeratx.com (GRTX) - Earnings per share growth in current year|Earnings per share growth rate in current year Molecular Templates Inc (MTEM)